A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia

Trial Profile

A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia

Suspended
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs BI 425809 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 04 Jan 2018 Planned End Date changed from 1 Feb 2019 to 5 Jul 2019.
    • 04 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 7 Jun 2019.
    • 22 Feb 2017 Planned End Date changed from 1 Mar 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top